Similarly, in the analysis of survival since tumor recurrence, reported in Figure 2C, the sample also coincidentally divided according to the expression of CD45+PD-L1+, dividing between those with positivity less than 44%, who survived for 10.6 ± 13.2 months, and those with CD45+PD-L1+ greater than or equal to 44%, whose survival was 33.5 ± 21.1 months (LogWorth 1.8288—equivalent to a p = 0.01483). This evidence concerns the gene PTPRC and neoplasm.